Article Text

other Versions

PDF
Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomide
  1. Jeffrey R Curtis (jcurtis{at}uab.edu)
  1. University of Alabama at Birmingham, United States
    1. Timothy Beukelman (tbeukelman{at}peds.uab.edu)
    1. University of Alabama at Birmingham, United States
      1. Alina Onofrei (aonofrei{at}umass.edu)
      1. University of Massachusetts, United States
        1. Sarah Cassell
        1. Los Alamos Medical Center, United States
          1. Jeffrey Greenberg (jgreenberg{at}nyu.edu)
          1. NYU, United States
            1. Arthur Kavanaugh
            1. University of California, United States
              1. George Reed (george.reed{at}umassmed.edu)
              1. University of Massachusetts, United States
                1. Vibeke Strand
                1. Stanford University, United States
                  1. Joel M Kremer (jkremer{at}joint-docs.com)
                  1. The Center for Rheumatology, Albany, United States

                    Abstract

                    Introduction: Potential hepatotoxicity associated with disease modifying anti-rheumatic drugs [DMARDs] requires laboratory monitoring. In rheumatoid and psoriatic arthritis [RA, PsA] patients, we examined the incidence of elevated alanine/aspartate aminotransferase (ALT/AST) enzymes associated with methotrexate (MTX), leflunomide (LEF), and MTX+LEF vs. other DMARDs.

                    Methods: RA and PsA patients enrolled in the Consortium of Rheumatology Researchers of North America (CORRONA) initiating DMARDs were identified. Abnormalities were identified when either was 1 or 2-fold time above the upper limits of normal (ULN). Odds ratios [OR] between MTX/LEF dose and elevated ALT/AST enzymes were estimated using generalized estimating equations. Interaction terms for use of MTX+LEF quantified the incremental risk of the combination compared to each individually.

                    Results: Elevated ALT/AST levels (>1x ULN) occurred in 22, 17, 31, and 14% RA patients receiving MTX, LEF, MTX+LEF, or neither, respectively; elevations were 2.76 fold (95% CI 1.84 - 4.15) more likely in PsA patients. Elevations > 2x ULN occurred in 1-2% of patients on MTX or LEF monotherapy compared to 5% with the combination. After multivariable adjustment and compared with either monotherapy, combination MTX + LEF was associated with greater risk according to MTX dose used as part of the combination: MTX 10-17.5mg/week, OR=2.91 (95% confidence interval [CI] 1.23-6.90) and MTX ≥20 mg/week, OR=3.98 (95% CI: 1.72-9.24).

                    Conclusions: 14-35% of RA and PsA patients initiating DMARD therapy developed abnormal ALT/AST levels. Risks were incrementally greater in those with PsA and in those receiving MTX (≥ 10mg/day) + LEF. These findings should help inform monitoring for potential hepatotoxicity in these patient populations.

                    Statistics from Altmetric.com

                    Request permissions

                    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.